MannKind Corporation Stock

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
4.08 USD -0.49% Intraday chart for MannKind Corporation -5.12% +12.09%
Sales 2024 * 260M Sales 2025 * 313M Capitalization 1.1B
Net income 2024 * 38M Net income 2025 * 73M EV / Sales 2024 * 3.29 x
Net cash position 2024 * 248M Net cash position 2025 * 273M EV / Sales 2025 * 2.66 x
P/E ratio 2024 *
30.9 x
P/E ratio 2025 *
17.9 x
Employees 413
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.49%
1 week-5.12%
Current month-9.93%
1 month-11.69%
3 months+21.79%
6 months-2.86%
Current year+12.09%
More quotes
1 week
3.97
Extreme 3.97
4.22
1 month
3.97
Extreme 3.97
5.11
Current year
3.17
Extreme 3.17
5.40
1 year
3.17
Extreme 3.17
5.75
3 years
2.49
Extreme 2.49
5.75
5 years
0.80
Extreme 0.8
6.25
10 years
0.67
Extreme 0.6662
57.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 16-03-13
Director of Finance/CFO 61 17-07-16
Chief Tech/Sci/R&D Officer 57 22-09-30
Members of the board TitleAgeSince
Director/Board Member 55 18-11-26
Director/Board Member 69 19-12-31
Director/Board Member 80 03-09-30
More insiders
Date Price Change Volume
24-04-18 4.08 -0.49% 1,292,719
24-04-17 4.1 +1.23% 2,453,484
24-04-16 4.05 -1.70% 1,324,771
24-04-15 4.12 -0.72% 1,600,922
24-04-12 4.15 -3.49% 2,108,364

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.08 USD
Average target price
7.083 USD
Spread / Average Target
+73.61%
Consensus